The totality of the data for AB928 and AB680 (both of which are in clinical development) indicate that 100-150 mg once-daily oral doses of AB928 and 10-20 mg intravenous AB680 every ~2 weeks should be explored in tumor types that either rely on multiple pathways for adenosine generation (AB928) or those that primarily utilize CD73 for that purpose (AB680). This evidence concerns the gene NT5E and neoplasm.